Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Ehlers Danlos Syndrome
•
Endocrinology
Would you start anabolic bone therapy in an patient with Ehlers Danlos, low bone density and no fracture history who is found to have "spongy soft bone" during spine surgery?
In this case, spine surgeon is recommending anabolic bone therapy post-op.
Related Questions
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
In a patient with a history of parathyroidectomy (due to primary hyperparathyroidism) with low T- scores and high risk of fractures, is there any contraindication to give teriparatide/Forteo if PTH is in normal range after surgery?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
Is there a maximum duration for raloxifene use?
Would you recommend waiting for a low Vitamin D level to correct to goal prior to giving a scheduled Prolia injection when transitioning a patient from Zolendronic acid to Prolia therapy for worsening osteoporosis?
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
How frequently do you monitor for hypocalcemia in patients on romosozumab?